Literature DB >> 16966266

Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.

Meletios Athanasios Dimopoulos1, Anastasia Pouli, Athanasios Anagnostopoulos, Panagiotis Repoussis, Argyris Symeonidis, Evangelos Terpos, Sosana Delimbasi, Friderikos Tsolakis, Theophanis Economopoulos, Constantinos Zervas.   

Abstract

There are limited reports of young patients with multiple myeloma (MM) who presented with multiple lytic bone lesions but without intervening infiltration of bone marrow, a pattern consisting of macrofocal MM. In order to clearly define the clinical and laboratory features and outcome of such patients, a retrospective analysis was performed of symptomatic patients with MM <or=40 years of age at diagnosis who received primary treatment over a 20-year period. Ten of 51 patients fulfilled the criteria of macrofocal MM. When compared to patients with typical MM, patients with macrofocal pattern were less anemic, none had hypercalcemia, renal impairment, elevated serum LDH or stage 3 according to the International Staging System (ISS). Patients with macrofocal MM usually had preserved the uninvolved immunoglobulins. An objective response to primary treatment was noted in 55% of patients with macrofocal MM and in 50% of patients without this pattern. The median survival of patients with typical MM was 57 months and is projected to exceed 8 years in patients with macrofocal MM (p = 0.087). With macrofocal MM despite multiple lytic bone lesions, patients have features of low tumor burden and improved survival when compared with young patients with typical MM.

Entities:  

Mesh:

Year:  2006        PMID: 16966266     DOI: 10.1080/10428190600647723

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Macrofocal multiple myeloma with frontal plasmacytoma.

Authors:  Kamal Kant Sahu; Pramod D A Kumar; Uday Yanamandra; Pankaj Malhotra
Journal:  BMJ Case Rep       Date:  2015-06-04

Review 3.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 4.  Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.

Authors:  Ankit K Dutta; Jean-Baptiste Alberge; Romanos Sklavenitis-Pistofidis; Elizabeth D Lightbody; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2022-01-11       Impact factor: 65.011

5.  Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.

Authors:  Junghoon Shin; Youngil Koh; Jeonghwan Youk; Miso Kim; Byung Soo Kim; Chul Won Choi; Hwa Jung Sung; Yong Park; Sung-Soo Yoon; Inho Kim
Journal:  Korean J Intern Med       Date:  2017-06-26       Impact factor: 2.884

Review 6.  Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Authors:  J Caers; B Paiva; E Zamagni; X Leleu; J Bladé; S Y Kristinsson; C Touzeau; N Abildgaard; E Terpos; R Heusschen; E Ocio; M Delforge; O Sezer; M Beksac; H Ludwig; G Merlini; P Moreau; S Zweegman; M Engelhardt; L Rosiñol
Journal:  J Hematol Oncol       Date:  2018-01-16       Impact factor: 17.388

7.  Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Authors:  L Sanoja-Flores; J Flores-Montero; J J Garcés; B Paiva; N Puig; A García-Mateo; O García-Sánchez; A Corral-Mateos; L Burgos; E Blanco; J Hernández-Martín; R Pontes; M Díez-Campelo; P Millacoy; P Rodríguez-Otero; F Prosper; J Merino; M B Vidriales; R García-Sanz; A Romero; L Palomera; R Ríos-Tamayo; M Pérez-Andrés; J F Blanco; M González; J J M van Dongen; B Durie; M V Mateos; J San-Miguel; A Orfao
Journal:  Blood Cancer J       Date:  2018-11-19       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.